Alexander I. Tröster
Barrow Neurological Institute
172 Papers
1.9K Citations
Alexander I. Tröster is an academic researcher from Barrow Neurological Institute. The author has contributed to research in topics: Deep brain stimulation & Parkinson's disease. The author has an hindex of 58, co-authored 169 publications. Previous affiliations of Alexander I. Tröster include University of Texas Southwestern Medical Center & University of Washington.
Chat about Author
Papers
Diagnostic Criteria for Mild Cognitive Impairment in Parkinson’s Disease: Movement Disorder Society Task Force Guidelines
Irene Litvan,Jennifer G. Goldman,Alexander I. Tröster,Ben Schmand,Daniel Weintraub,Ronald C. Petersen,Brit Mollenhauer,Charles H. Adler,Karen Marder,Caroline H. Williams-Gray,Dag Aarsland,Jaime Kulisevsky,Maria C. Rodriguez-Oroz,David J. Burn,Roger A. Barker,Murat Emre +15 more
TL;DR: These diagnostic criteria will support future research efforts to identify at the earliest stage those PD patients at increased risk of progressive cognitive decline and dementia who may benefit from clinical interventions at a predementia stage.
Criteria for the diagnosis of corticobasal degeneration.
Melissa J. Armstrong,Irene Litvan,Anthony E. Lang,Thomas H. Bak,Kailash P. Bhatia,Barbara Borroni,Adam L. Boxer,Dennis W. Dickson,Murray Grossman,Mark Hallett,Keith A. Josephs,Andrew Kertesz,Suzee E. Lee,Bruce L. Miller,Stephen G. Reich,David E. Riley,Eduardo Tolosa,Alexander I. Tröster,Marie Vidailhet,William J. Weiner +19 more
TL;DR: Clinical CBD phenotypes and features were combined to create 2 sets of criteria: more specific clinical research criteria for probable CBD and broader criteria for possible CBD that are more inclusive but have a higher chance to detect other tau-based pathologies.
Symptom validity assessment: practice issues and medical necessity NAN policy & planning committee.
Shane S. Bush,Ronald M. Ruff,Alexander I. Tröster,Jeffrey T. Barth,Sandra P. Koffler,Neil H. Pliskin,Cecil R. Reynolds,Cheryl H. Silver +7 more
TL;DR: In this paper, an assessment of response validity, as a component of a medically necessary evaluation, is medically necessary, and when determined by the neuropsychologist to be necessary for the assessment of symptom validity tests are also medically necessary.
844
MDS Task Force on Mild Cognitive Impairment in Parkinson’s disease: Critical Review of PD-MCI
Irene Litvan,Dag Aarsland,Charles H. Adler,Jennifer G. Goldman,Jaime Kulisevsky,Brit Mollenhauer,Maria C. Rodriguez-Oroz,Alexander I. Tröster,Daniel Weintraub +8 more
TL;DR: It is found that a high proportion of patients with Parkinson's disease–mild cognitive impairment progress to dementia in a relatively short period of time, and patients at risk of progressing to dementia are at risk.
Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy
Vicenta Salanova,Thomas C. Witt,Robert M. Worth,Thomas R. Henry,Robert E. Gross,Jules M. Nazzaro,Douglas Labar,Michael R. Sperling,Ashwini Sharan,Evan Sandok,Adrian Handforth,John M. Stern,Steve Chung,Jaimie M. Henderson,Jacqueline A. French,Gordon H. Baltuch,William E. Rosenfeld,Paul A. Garcia,Nicholas M. Barbaro,Nathan B. Fountain,W. Jeffrey Elias,Robert R. Goodman,John R. Pollard,Alexander I. Tröster,Christopher P. Irwin,Kristin Lambrecht,Nina M. Graves,Robert S. Fisher +27 more
TL;DR: This long-term follow-up provides Class IV evidence that for patients with drug-resistant partial epilepsy, anterior thalamic stimulation is associated with a 69% reduction in seizure frequency and a 34% serious device-related adverse event rate at 5 years.